RPL 554

Drug Profile

RPL 554

Alternative Names: RPL-554

Latest Information Update: 04 Jan 2017

Price : $50

At a glance

  • Originator Vernalis
  • Developer Verona Pharma
  • Class Antiallergics; Antiasthmatics; Imines; Isoquinolines; Small molecules; Urea compounds
  • Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Allergic rhinitis; Asthma

Highest Development Phases

  • Phase II Allergic asthma; Asthma; Chronic obstructive pulmonary disease
  • Preclinical Cystic fibrosis
  • No development reported Allergic rhinitis

Most Recent Events

  • 28 Sep 2016 Preclinical trials in Chronic obstructive pulmonary disease in United Kingdom (Inhalation) before September 2016
  • 28 Sep 2016 Preclinical trials in Cystic fibrosis in United Kingdom (Inhalation) before September 2016
  • 27 Sep 2016 Verona Pharma and Cystic Fibrosis Trust plan a phase IIa trial for Cystic fibrosis in United Kingdom (Inhalation) (NCT02919995)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top